Egler had a BMI of 25 and shed 15 pounds over six weeks on a microdose protocol
Emerging therapies, such as Tirzepatide, a dual GLP-1/GIP agonist, and Orforglipron, a nonpeptide oral GLP-1 RA, continue to expand the potential of this medication class in treating metabolic diseases (23)(24)
Resuming GLP-1 Therapy After Weight Regain If weight has already returned after stopping, restarting GLP-1 therapy does work, but your body may require a longer titration period and higher doses to achieve the same appetite suppression as before
The SURMOUNT-1 study reported dose-dependent triglyceride reductions of 15-25% with the highest doses (10-15 mg weekly), alongside LDL cholesterol decreases of 6-10%
But we've come up with a few strategies to avoid complete chaos
If considering a dose reduction for maintenance: Wait until weight has stabilized for at least 4 weeks at your current dose Reduce by one dose step (e.g., 12mg to 8mg), do not jump multiple steps Monitor weight closely for 8 weeks after the reduction If weight begins to increase, return to the previous maintenance dose The phase 3 trials specifically tested 4mg as a maintenance dose, suggesting Lilly sees viability in lower maintenance doses What happens if you stop Weight regain after discontinuing GLP-1 agonists is well documented with semaglutide and tirzepatide
